THU0378 Interleukin-6 blocking therapy by tocilizumab in patients with multicentric castleman’s disease results in a significant decrease in serum levels of IgG4 and IGE

Abstract

BackgroundMulticentric Castleman disease (MCD) is a rare lymphoproliferative disorder characterized by systemic lymphadenopathy, constitutional inflammatory symptoms, and abnormal laboratories such as hyper-γ-globulinemia, increases in various auto-antibodies as well as acute...